Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.43 |
| ▸ | RAB9A | P51151 | 7/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | F9 | P00740 | 3/20 | 0.35 |
| ▸ | F10 | P00742 | 2/20 | 0.35 |
| ▸ | DAO | P14920 | 2/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.32 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.32 |
| ▸ | HAO1 | Q9UJM8 | 3/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22608654 | 0.93 | NPC1 (0.49) | NPC1RAB9AKDM4EHKDC1TDP1 | |
| SCHEMBL22807346 | 0.84 | NPC1 (0.36) | NPC1RAB9AKDM4EHKDC1TDP1 | |
| Trifluoroacetic Acid SCHEMBL22807475 | 0.77 | HAO1 (0.53) | HAO1 | |
| Trifluoroacetic Acid SCHEMBL22608699 | 0.73 | HAO1 (0.41) | HAO1 | |
| SCHEMBL22608518 | 0.72 | RHEB (0.48) | HAO1 | |
| Trifluoroacetic Acid SCHEMBL5025946 | 0.72 | NPC1 (0.82) | NPC1RAB9AKDM4EHKDC1TDP1 | |
| Trifluoroacetic Acid SCHEMBL22608382 | 0.70 | DPP4 (0.38) | NPC1RAB9AKDM4EL3MBTL1GFER | |
| SCHEMBL22608203 | 0.70 | HAO1 (0.39) | TDP1HAO1 | |
| Trifluoroacetic Acid SCHEMBL5028767 | 0.69 | NPC1 (0.54) | NPC1RAB9AKDM4EHKDC1TDP1 | |
| SCHEMBL22608661 | 0.69 | HAO1 (0.56) | HAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| EP-3986863-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BioMarin Pharmaceutical Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114258390-A | Glycolate oxidase inhibitors for disease treatment | 生物马林药物股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| CN-111788187-A | Glycolate oxidase inhibitors for disease treatment | 生物马林药物股份有限公司 | 2020-10-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | NPC1 1158/4885RAB9A 3923/4885KDM4E 3645/4885 |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | NPC1 1113/4885RAB9A 3978/4885KDM4E 3325/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | NPC1 1158/4885RAB9A 3923/4885KDM4E 3645/4885 |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | NPC1 1158/4885RAB9A 3923/4885KDM4E 3645/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | NPC1 1158/4885RAB9A 3923/4885KDM4E 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.